• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Sonus heads north to ATL territory

Article

Ultrasound contrast agent developerSonus Pharmaceuticals is moving its corporate headquarters thismonth. The move, to the Seattle suburb of Bothell, WA, will makeSonus a close neighbor of ultrasound company ATL, also based inBothell. Sonus previously

Ultrasound contrast agent developerSonus Pharmaceuticals is moving its corporate headquarters thismonth. The move, to the Seattle suburb of Bothell, WA, will makeSonus a close neighbor of ultrasound company ATL, also based inBothell.

Sonus previously was headquartered in Costa Mesa, CA. The company,founded by Omniscan inventor Dr. Steven Quay, is developing aline of intravascular ultrasound contrast agents.

The company's first agent, EchoGen, is based on an emulsionthat turns into echogenic microbubbles when injected (SCAN 1/19/94).Sonus filed an investigational new drug (IND) application forEchoGen earlier this year.

The ATL and Sonus facilities are located within a stone's throwof each other, according to ATL president David Perozek. WhileATL and Sonus employees can look forward to sharing the sunnyskies for which the Pacific Northwest is famous, the relationshipbetween the companies will go no farther than that, at least forthe time being.

ATL and Sonus do not have a business relationship and haveno plans to develop one in the near future, Perozek said.

Sonus representatives were not available for comment.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.